Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data
- 1 July 2019
- journal article
- research article
- Published by Elsevier in The Lancet Haematology
- Vol. 6 (7) , e359-e365
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatmentJournal of Thrombosis and Thrombolysis, 2016
- A review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough?The Anatolian Journal of Cardiology, 2015
- Effect of body weight on efficacy and safety of direct oral anticoagulants in the treatment of patients with acute venous thromboembolism: A meta-analysis of randomized controlled trialsAnnals of Medicine, 2015
- Oral Apixaban for the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2013
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismNew England Journal of Medicine, 2012
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Oral Rivaroxaban for Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2010
- Dabigatran versus Warfarin in the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2009
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009